Glycoprotein VI and uses thereof

Details Glycoprotein VI and uses thereof Glycoprotein VI and uses thereof

2006-06-29

2009-10-06

Huynh, Phuong (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S135100, C424S141100, C424S142100, C424S143100, C424S178100, C424S179100, C424S181100, C424S183100, C435S810000, C530S387100, C530S388100, C530S388150, C530S388220, C530S391100, C530S391300, C530S391700

Reexamination Certificate

active

07597888

ABSTRACT:
The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

REFERENCES:
patent: 4474893 (1984-10-01), Reading
patent: 4676980 (1987-06-01), Segal et al.
patent: 4714681 (1987-12-01), Reading
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4925648 (1990-05-01), Hansen et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter
patent: 5272057 (1993-12-01), Smulson
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5459039 (1995-10-01), Modrich et al.
patent: 5516637 (1996-05-01), Huang et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5573920 (1996-11-01), Randle
patent: 5580717 (1996-12-01), Dower et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5601819 (1997-02-01), Wong et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5658727 (1997-08-01), Barbas et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5698426 (1997-12-01), Huse
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5780225 (1998-07-01), Wigler et al.
patent: 5821047 (1998-10-01), Garrard et al.
patent: 5854005 (1998-12-01), Coller
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5969108 (1999-10-01), McCafferty et al.
patent: 5976532 (1999-11-01), Coller et al.
patent: 6245527 (2001-06-01), Busfield et al.
patent: 6383779 (2002-05-01), Busfield et al.
patent: 6989144 (2006-01-01), Busfield et al.
patent: 7101549 (2006-09-01), Gill et al.
patent: 7291714 (2007-11-01), Busfield et al.
patent: 2006/0216291 (2006-09-01), Busfield et al.
patent: O 125 023 (1984-11-01), None
patent: 0 171 496 (1986-02-01), None
patent: 0 173 494 (1986-03-01), None
patent: 0 184 187 (1986-06-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 87/02671 (1987-05-01), None
patent: WO 90/02809 (1990-03-01), None
patent: WO 91/00360 (1991-01-01), None
patent: WO 91/10737 (1991-07-01), None
patent: WO 91/17271 (1991-11-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 92/05793 (1992-04-01), None
patent: WO 92/08802 (1992-05-01), None
patent: WO 92/09690 (1992-06-01), None
patent: WO 92/15679 (1992-09-01), None
patent: WO 92/18619 (1992-10-01), None
patent: WO 92/20791 (1992-11-01), None
patent: WO 92/22324 (1992-12-01), None
patent: WO 93/01288 (1993-01-01), None
patent: WO 93/11236 (1993-06-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 95/11259 (1995-04-01), None
patent: WO 95/15982 (1995-06-01), None
patent: WO 95/20401 (1995-08-01), None
patent: WO 97/13844 (1997-04-01), None
patent: WO 99/11662 (1999-11-01), None
patent: WO 00/68377 (2000-11-01), None
patent: WO 2005/111083 (2005-11-01), None
Gruener, S., M.D., et al., “Anti-Glycoprotein VI Treatment Severely Compromises Hemostasis in Mice With Reduced α2β1 Levels or Concomitant Aspirin Therapy”,Circulation, 110:2946-2951 (May 21, 2004).
Nieswandt, B. et al., “Expression and Function of the Mouse Collegen Receptor Glycoprotein VI Is Strictly Dependent on Its Association with the FcRγ Chain”,J. Biol. Chem., 275(31):23998-24002 (JBC Papers in Press, USA) (May 23 2000).
Adams MD et al., “Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence”, Nature. Sep. 28, 1995; 377(6547 Suppl):3-174.
Altschul SF at al., “Basic local alignment search tool”, J Mol Biol. Oct. 5, 1990; 215(3):403-10.
Altschul SF et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”, Nucleic Acids Res. Sep. 1, 1997;25(17):3389-402.
Ames et al., 1995, ‘Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoalobulins’, J. Immunol. Methods 184:177-186.
Arai M et al., “Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency”, BR J Haematol. Jan. 1995; 89(1):124-30.
Arnon et al., 1985, ‘Monoclonal antibodies for immunotargeting of drugs In cancer therapy’, in: Monoclonal Antibodies and Cancer Therapv. Reisfeld et al. eds. Alan R. Liss. Inc., pp. 243-256.
Asselin J et al., “Monomeric (glycine-proline-hydroxyproline) 10 repeat sequence is a partial agonist of the platelet collagen receptor glycoprotein VI”, Biochem J. Apr. 15, 1999;339 (Pt 2):413-8.
Ausubel et al, (eds.), 1989, in: Current Protocols In Molecular Biology, Green Publishing Associates, Inc. and John Wiley & Sons Inc., NY p. 8.3.1-6.3.6 and 2.10.3.
Baldwin et al., (eds.), 1985, “Analysis, results and future prospective of the therapeutic use of radiolabeled antibody in cancer therapv”, In: Monoclonal Antibodies for Cancer Detection and Therapv. Academic Press, pp. 303-316.
Barany F., “Genetic disease detection and DNA amplification using cloned thermostable ligase”, Proc Natl Acad Sci USA. Jan. 1, 1991; 88(1):189-93.
Barnes MJ et al., “The collagen-platelet interaction”, Curr Opin Hematol. Sep. 1998;5(5):314-20.
Beidler et al., 1988, “Cloning and high level expression of a chimeric antibody with specificity for human carcinoembryonic antigen”, J. Immunol. 141;4053-4060.
Better et al. 1988 “Escherichia colisecretion of an active chimeric antibody fragmen”, Science 240: 1041-1 043.
Briddon SJ, et al., “Evidence for the involvement of p59fyn and p53/561yn in collagen receptor signalling in human platelets”, Biochem J. Feb. 15, 1999; 338 (Pt 1): 203-9.
Brinkmann et al. 1995 “Phage displav of disulfide stabilized Fv fragments”, J. Immunol. Meth. 182:41-50.
Burton and Barbas, 1994 “Human antibodies from combinatorial libraries”, Adv. Immunol. 57:191-280.
Carlsson LE et al., “Heparin-induced thrombocytopenia: new insights into the impact of the FcyRlfa-R-H131 polymorphism”, Blood. Sep. 1, 1998; 92(5): 1526.31.
Chiang TM, et al., “Isolation and purification of collagen alpha 1(1) receptor from human platelet membrane”, J Bioi Chem. 1982 Ju1 10; 257(13): 7581-6.
Chiang TM et al., “Cloning, characterization, and functional studies of a nonintegrin platelet receptor for type I collagen”, J Clin Invest. Aug. 1997; 100(3): 514-521.
Clemetson KJ, “Platelet activation: signal transduction via membrane receptors”, Thromb Haemost. Jul. 1995; 74(1): 111-6.
Clemetson JM et al., “The Platelet Collagen Receptor Glycoprotein VI is a Member of the Immunoglobulin Superfamily Closely Related to FcalphaR and the Natural Killer Receptors”, J Biol Chem. Oct. 8, 1999; 274(41):29019-29024.
Clemetson KJ et al., “Characterization of the platelet membrane glycoprotein abnormalities In Bernard-Soulier syndrome and comparison with normal by surface-labeling techniques and high=resolution two-dimensional gel electrophoresis”, J Clin Invest. Aug. 1982; 70(2):304-11.
Cole et al., 1985, “The EBV-hybridoma technique and Its application to human lung cancer”, in: Monoclonal Antibodies and Cancer Therapv, Alan R. Liss, Inc. PD. 77-96.
Collgan et al., (eds.), 1992, Current Protocols in Immunoloov, John Wiley and Sons, New York p. 2.5.1-2.5.11.
Coller et al.

Affiliated with

Also associated with

Rating

Glycoprotein VI and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Glycoprotein VI and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycoprotein VI and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4107369